| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8674514 | Nutrition, Metabolism and Cardiovascular Diseases | 2018 | 22 Pages |
Abstract
In conclusion the carcinogenic risk of long-acting analogs, and specifically glargine, can be neither confirmed nor excluded. A personalized and shared decision, considering all the individual risk factors (metabolic and non-metabolic), is the suggestion for the clinician.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
L. Sciacca, V. Vella, L. Frittitta, A. Tumminia, L. Manzella, S. Squatrito, A. Belfiore, R. Vigneri,